Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement